LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Elderly onset of MELAS carried an M.3243A >G mutation in a female with deafness and visual deficits: A case report.

    Zijun, Lin / Xu, Yi / Yujia, Yang / Zhiqiang, Xu

    Clinical case reports

    2024  Volume 12, Issue 3, Page(s) e8438

    Abstract: Key clinical message: MELAS is a disorder with clinical variability that also responsible for a significant portion of unexplained hereditary or childhood-onset hearing loss. Although patients typically present in childhood, the first stroke-like ... ...

    Abstract Key clinical message: MELAS is a disorder with clinical variability that also responsible for a significant portion of unexplained hereditary or childhood-onset hearing loss. Although patients typically present in childhood, the first stroke-like episode can occur later in life in some patients, potentially related to a lower heteroplasmy level. It is crucial to consider MELAS as a potential cause of stroke-like events if age at presentation and symptoms are atypical, especially among middle-aged patients without vascular risk factors.
    Abstract: MELAS syndrome (mitochondrial encephalopathy with lactic acidosis and stroke-like episodes) is a rare genetic condition that most patients develop stroke-like episodes before the age of 40. We report a 52-year-old female with a documented 40-year history of progressive sensorineural hearing loss, developed a visual field deficit and stroke-like events in her middle age who finally diagnosed was MELAS. The patient was started on vitamin E, l-carnitine, l-arginine, and coenzyme Q10 that gradually improved before dismissal from the hospital. This case highlights the importance of considering MELAS as a potential cause of stroke-like events if imaging findings are atypical for cerebral infarction, especially among middle-aged patients without vascular risk factors and an unusual cause of progressive sensorineural hearing loss.
    Language English
    Publishing date 2024-03-13
    Publishing country England
    Document type Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.8438
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Speculative Exploration on Future Sustainable Human-Machine Interface Design in Automated Shuttle Buses

    Ming Yan / Zijun Lin / Peng Lu / Mansu Wang / Lucia Rampino / Giandomenico Caruso

    Sustainability, Vol 15, Iss 5497, p

    2023  Volume 5497

    Abstract: Automated Shuttle buses (ASB) are considered an essential and sustainable direction for the future application of autonomous driving technology in public transportation. As the driver’s role gradually decreases and disappears, the Human–Machine Interface ...

    Abstract Automated Shuttle buses (ASB) are considered an essential and sustainable direction for the future application of autonomous driving technology in public transportation. As the driver’s role gradually decreases and disappears, the Human–Machine Interface (HMI) for information exchange and communication between users and ASB takes a more prominent role and progressively becomes a hotspot in research. However, the unpredictability and complexity of autonomous driving, an exceptionally fast-growing technology, have hindered its future study. This work first reviewed related literature in three categories: internal, external, and station of the ASB. Secondly, the importance of systemic and speculative design is affirmed by exploring existing HMI designs for ASB. Thirdly, the concepts for ASB resulting from three parallel workshops were analyzed. Finally, online questionnaires and interviews completed the critical reflection and discussion. The results show that the introduction of tools and methods related to systemic and speculative design into the design process of the HMI for ASB may help designers to think critically about the future uncertainty of ASB and to deal with the complexity of the system.
    Keywords automated shuttle buses ; human-machine interface ; systemic design ; speculative design ; user experience ; Environmental effects of industries and plants ; TD194-195 ; Renewable energy sources ; TJ807-830 ; Environmental sciences ; GE1-350
    Subject code 670
    Language English
    Publishing date 2023-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Celastrol Inhibits Canine Mammary Tumor Cells by Inducing Apoptosis via the Caspase Pathway

    Guoxing Ou / Xianyu Jiang / Ang Gao / Xiaolong Li / Zijun Lin / Shimin Pei

    Frontiers in Veterinary Science, Vol

    2022  Volume 8

    Abstract: Canine mammary tumor is a serious disease threatening the health of dogs and can be used as a research model for human breast cancer. The study of canine mammary tumor has a role in improving the welfare of dogs. Most common canine mammary tumor ... ...

    Abstract Canine mammary tumor is a serious disease threatening the health of dogs and can be used as a research model for human breast cancer. The study of canine mammary tumor has a role in improving the welfare of dogs. Most common canine mammary tumor chemotherapy drugs have limited effects and drug resistance. Celastrol is an extract of Tripterygium wilfordii, which has a wide range of biological activities, including significant anti-tumor effects. At present, celastrol has not been used in the clinical treatment for canine mammary tumor. This study investigated the anti-tumor properties of celastrol through in vitro assay of cell proliferation inhibition, cell colony, cell migration, and invasion; flow cytometry, qPCR, and Western Blot methods were used to explore the anti-tumor mechanism of celastrol. The results showed that celastrol can inhibit the proliferation of canine mammary tumor cells in vitro, and decrease the migration and invasion ability of canine mammary tumor cells. We also found that celastrol can upregulate Cleaved Caspase-3 and Cleaved Caspase-9 protein expression levels to promote cell apoptosis, and can regulate cell cycle-related proteins to induce cell cycle arrest. In summary, celastrol may inhibit canine mammary tumor cells through the Caspase pathway, providing a new direction for anti-canine mammary tumor drugs, and is expected to become a new anti-cancer drug for canine mammary tumors.
    Keywords canine mammary tumor ; celastrol ; apoptosis ; caspase pathway ; anti-tumor ; Veterinary medicine ; SF600-1100
    Language English
    Publishing date 2022-02-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance

    Jianyu Peng / Zijun Lin / Weichun Chen / Jie Ruan / Fan Deng / Lin Yao / Minla Rao / Xingdong Xiong / Shun Xu / Xiangning Zhang / Xinguang Liu / Xuerong Sun

    Heliyon, Vol 9, Iss 7, Pp e17714- (2023)

    2023  

    Abstract: More than one half melanoma patients have BRAF gene mutation. BRAF inhibitor vemurafenib is an effective medication for these patients. However, acquired resistance is generally inevitable, the mechanisms of which are not fully understood. Cell ... ...

    Abstract More than one half melanoma patients have BRAF gene mutation. BRAF inhibitor vemurafenib is an effective medication for these patients. However, acquired resistance is generally inevitable, the mechanisms of which are not fully understood. Cell senescence and senescence-associated secretory phenotype (SASP) are involved in extensive biological functions. This study was designed to explore the possible role of senescent cells in vemurafenib resistance. The results showed that vemurafenib treatment induced BRAF-mutant but not wild-type melanoma cells into senescence, as manifested by positive β-galactosidase staining, cell cycle arrest, enlarged cellular morphology, and cyclin D1/p-Rb pathway inhibition. However, the senescent cells induced by vemurafenib (SenV) did not display DNA damage response, p53/p21 pathway activation, reactive oxygen species accumulation, decline of mitochondrial membrane potential, or secretion of canonical SASP cytokines. Instead, SenV released other cytokines, including CCL2, TIMP2, and NGFR, to protect normal melanoma cells from growth inhibition upon vemurafenib treatment. Xenograft experiments further confirmed that vemurafenib induced melanoma cells into senescence in vivo. The results suggest that vemurafenib can induce robust senescence in BRAFV600E melanoma cells, leading to the release of resistance-conferring cytokines. Both the senescent cells and the resistant cytokines could be potential targets for tackling vemurafenib resistance.
    Keywords Melanoma ; Resistance ; Vemurafenib ; Cell senescence ; Cytokines ; BRAF inhibitors ; Science (General) ; Q1-390 ; Social sciences (General) ; H1-99
    Subject code 610
    Language English
    Publishing date 2023-07-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top